<DOC>
	<DOCNO>NCT00277511</DOCNO>
	<brief_summary>Primary objective : - To investigate microbiological efficacy , assess eradication rate base microbiologically evaluable patient 1 month post treatment oral Levofloxacin 500 mg male adult chronic bacterial prostatitis ( CBP , category II ) Secondary objective : - To investigate microbiological efficacy , assess eradication rate base microbiologically evaluable patient 6 month post treatment oral Levofloxacin 500 mg male adult chronic bacterial prostatitis ( CBP , category II ) . - To assess clinical response rate base resolution sign symptoms 2 week treatment ; 5-12 day , 1 month , 3 month 6 month post treatment oral Levofloxacin 500 mg male adult chronic bacterial prostatitis ( CBP , category II ) . - To assess safety Levofloxacin 500 mg basis adverse event , standard clinical chemistry , hematology , urinalysis vital sign male adult chronic bacterial prostatitis ( CBP , category II ) .</brief_summary>
	<brief_title>Levofloxacin , Chronic Bacterial Prostatitis</brief_title>
	<detailed_description />
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Subjects meet follow criterion consider enrollment study : A clinical diagnosis chronic prostatitis evidence follow criterion : clinical sign symptom prostatitis history chronic prostatitis define : symptomatic prostatitis ( clinical diagnosis prostatitis make least one previous episode episode last four week two episode previous twelve month ) leucocyturia greater/equal 10 WBC/HPF x 400 Laboratory evidence prostatitis Candidate appropriate oral therapy . OTC medication chronic prostatitis ( antibiotic ) , subject receiving must continue throughout study dose discontinue prior study entry . Subjects present follow include study : Need parenteral therapy treatment chronic bacterial prostatitis ( CBP , Category II ) Subjects pathogen know suspected resistant study drug Requirement second systemic antibacterial regimen Any condition may interfere evaluation study drug include transurethral prostatectomy within 6 month enrollment , presence permanent transurethral catheter history cystostomy nephrostomy Taking medication may effect bladder prostate function ( e.g . hormone therapy anticholinergic alphablocker ) Patients receive saw palmetto time study entry start treatment saw palmetto within 10 week study entry Known prostatic carcinoma The presence another infection require therapy antibacterial study drug Greater 24 hour potentially effective therapy within seven day prior study documented evidence resistant organism clinical failure five day previous antibacterial therapy History hypersensitivity investigational product drug similar chemical structure History tendonitis tendon rupture Treatment quinolones last 14 day study entry Likelihood require treatment study period drug permit clinical study protocol . Treatment investigational product last 30 day study entry Clinically relevant cardiovascular , hepatic , neurologic , endocrine major systemic disease make implementation protocol interpretation study result difficult History drug alcohol abuse Impaired hepatic function , show : AST ( SGOT ) greater/equal 3 time upper limit reference range ALT ( SGPT ) greater/equal 3 time upper limit reference range bilirubin great 51 Âµmol/l , i.e. , great 3 mg/dl ( except Gilbert disease ) hepatic encephalopathy Impaired renal function , show either creatinine clearance small 50 ml/min undergoing hemodialysis peritoneal dialysis ( creatinine clearance may estimate formula nomogram ) Underweight ( 40 kg less )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>